Literature DB >> 26770324

Analysis of differentially expressed genes based on microarray data of glioma.

Chun-Ming Jiang1, Xiao-Hua Wang1, Jin Shu1, Wei-Xia Yang2, Ping Fu3, Li-Li Zhuang1, Guo-Ping Zhou1.   

Abstract

Glioma represents one of the main causes of cancer-related death worldwide. Unfortunately, its exact molecular mechanisms remain poorly understood, which limits the prognosis and therapy. This study aimed to identify the critical genes, transcription factors and the possible biochemical pathways that may affect glioma progression at transcription level. After downloading micro-array data from Gene Expression Omnibus (GEO), the differentially expressed genes (DEGs) between glioma and normal samples were screened. We predicted novel glioma-related genes and carried on online software DAVID to conduct GO enrichment and transcription factor analysis of these selected genes. String software was applied to construct a PPI protein interaction network, as well as to find the key genes and transcription factors in the regulation of glioma. A total of 97 DEGs were identified associated with cancer, the GO enrichment analysis indicated these DEGs were mainly relevant to immune responses as well as regulation of cell growth. In addition, the transcription factor analysis showed these DEGs were regulated by the binding sites of transcription factors GLI2, SP1, SMAD7, SMAD3, RELA, STAT5B, CTNNB1, STAT5A, TFAP2A and SP3. PPI protein interaction network analysis demonstrated the hub nodes in the interaction network were EGFR, TGFB1, FN1 and MYC. The hub DEGs may be the most critical in glioma and could be considered as drug targets for glioma therapy after further exploration. Besides, with the identification of regulating transcription factors, the pathogenesis of glioma at transcription level might be brought to light.

Entities:  

Keywords:  EGFR; Glioma; differentially expressed genes; gene expression profiles

Year:  2015        PMID: 26770324      PMCID: PMC4694224     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  35 in total

1.  Cytoscape: a software environment for integrated models of biomolecular interaction networks.

Authors:  Paul Shannon; Andrew Markiel; Owen Ozier; Nitin S Baliga; Jonathan T Wang; Daniel Ramage; Nada Amin; Benno Schwikowski; Trey Ideker
Journal:  Genome Res       Date:  2003-11       Impact factor: 9.043

2.  An imbalance between Smad and MAPK pathways is responsible for TGF-beta tumor promoting effects in high-grade gliomas.

Authors:  T Nickl-Jockschat; F Arslan; A Doerfelt; U Bogdahn; A Bosserhoff; P Hau
Journal:  Int J Oncol       Date:  2007-02       Impact factor: 5.650

3.  Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets.

Authors:  Dominique B Hoelzinger; Luigi Mariani; Joachim Weis; Tanja Woyke; Theresa J Berens; Wendy S McDonough; Andrew Sloan; Stephen W Coons; Michael E Berens
Journal:  Neoplasia       Date:  2005-01       Impact factor: 5.715

4.  Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene.

Authors:  S Dennler; S Itoh; D Vivien; P ten Dijke; S Huet; J M Gauthier
Journal:  EMBO J       Date:  1998-06-01       Impact factor: 11.598

5.  High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.

Authors:  Alejandra Bruna; Rachel S Darken; Federico Rojo; Alberto Ocaña; Silvia Peñuelas; Alexandra Arias; Raquel Paris; Avelina Tortosa; Jaume Mora; Jose Baselga; Joan Seoane
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

Review 6.  Transforming growth factor beta (TGF-beta) and inflammation in cancer.

Authors:  Brian Bierie; Harold L Moses
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-16       Impact factor: 7.638

7.  The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma.

Authors:  P Jachimczak; U Bogdahn; J Schneider; C Behl; J Meixensberger; R Apfel; R Dörries; K H Schlingensiepen; W Brysch
Journal:  J Neurosurg       Date:  1993-06       Impact factor: 5.115

8.  Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction.

Authors:  Jörg van den Boom; Marietta Wolter; Rork Kuick; David E Misek; Andrew S Youkilis; Daniel S Wechsler; Clemens Sommer; Guido Reifenberger; Samir M Hanash
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

9.  Overexpression of phospholipase D enhances matrix metalloproteinase-2 expression and glioma cell invasion via protein kinase C and protein kinase A/NF-kappaB/Sp1-mediated signaling pathways.

Authors:  Mi Hee Park; Bong-Hyun Ahn; Yong-Kil Hong; Do Sik Min
Journal:  Carcinogenesis       Date:  2009-01-06       Impact factor: 4.944

10.  EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas.

Authors:  Kaiming Xu; Hui-Kuo G Shu
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

View more
  8 in total

1.  Regulatory interactions between long noncoding RNA LINC00968 and miR-9-3p in non-small cell lung cancer: A bioinformatic analysis based on miRNA microarray, GEO and TCGA.

Authors:  Dong-Yao Li; Wen-Jie Chen; Jun Shang; Gang Chen; Shi-Kang Li
Journal:  Oncol Lett       Date:  2018-04-12       Impact factor: 2.967

2.  Knockdown of EWSR1/FLI1 expression alters the transcriptome of Ewing sarcoma cells in vitro.

Authors:  Jihan Wang; Wenyan Jiang; Yuzhu Yan; Chu Chen; Yan Yu; Biao Wang; Heping Zhao
Journal:  J Bone Oncol       Date:  2016-05-30       Impact factor: 4.072

3.  Gene expression meta-analysis in diffuse low-grade glioma and the corresponding histological subtypes.

Authors:  Siqi Wang; Feng Jin; Wenliang Fan; Fang Liu; Yan Zou; Xuehan Hu; Haibo Xu; Ping Han
Journal:  Sci Rep       Date:  2017-09-18       Impact factor: 4.379

4.  Personalized anticancer therapy selection using molecular landscape topology and thermodynamics.

Authors:  Edward A Rietman; Jacob G Scott; Jack A Tuszynski; Giannoula Lakka Klement
Journal:  Oncotarget       Date:  2017-03-21

5.  Prediction and analysis of hub genes between glioblastoma and low-grade glioma using bioinformatics analysis.

Authors:  Baowei Xu
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

6.  A comprehensive analysis of the predicted targets of miR-642b-3p associated with the long non-coding RNA HOXA11-AS in NSCLC cells.

Authors:  Yu Zhang; Jie Luo; Xiao Wang; Han-Lin Wang; Xiu-Ling Zhang; Ting-Qing Gan; Gang Chen; Dian-Zhong Luo
Journal:  Oncol Lett       Date:  2018-02-22       Impact factor: 2.967

7.  Effects of the MAML2 genetic variants in glioma susceptibility and prognosis.

Authors:  Ming Zhang; Yonglin Zhao; Junjie Zhao; Tingqin Huang; Xiaoye Guo; Xudong Ma; Yuan Wu
Journal:  Biosci Rep       Date:  2019-10-30       Impact factor: 3.840

8.  STAT5A induced LINC01198 promotes proliferation of glioma cells through stabilizing DGCR8.

Authors:  Cheng Tan; Yimeng Dai; Xiaoyang Liu; Guifang Zhao; Weiyao Wang; Jia Li; Ling Qi
Journal:  Aging (Albany NY)       Date:  2020-04-04       Impact factor: 5.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.